ARHGEF2 and cancer: As opposed to Ras GTPases, which are hyperactivated in approximately a quarter of all human cancers [144], dysregulation of Rho GTPase signaling has mainly been attributed to Rho GTPase overexpression or altered GEF or GAP levels.